Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial
Latest Information Update: 23 Oct 2021
At a glance
- Drugs Losartan (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms STOP-NAFLD
- 23 Sep 2021 Status changed from completed to discontinued.
- 05 Jun 2020 Status changed from active, no longer recruiting to completed.
- 30 Apr 2020 Planned End Date changed from 28 Feb 2021 to 31 May 2020.